Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

25.05.2020 | original report

Comparison of outcomes of two non-BCNU-containing conditioning regimens used in autologous stem cell transplantation for relapsed/refractory lymphoma

verfasst von: Amro Mohamed Sedky El-Ghammaz, Maha El-Zimaity, Afaf Abdel-Aziz Abdel-Ghaffar

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Summary Background Methods Results Conclusion

A comparison was performed of outcomes of two non-BCNU-containing conditioning regimens used in autologous stem cell transplantation (ASCT) for lymphoma due to the lack of superiority of any regimen over others in the setting of the global BCNU shortage.
CCVP-16 and LEAM conditioning regimens were compared in 55 relapsed/refractory lymphoma patients regarding engraftment timing, hospitalization duration, toxicity profile, disease progression and survival.
There was insignificant difference between the two regimens regarding engraftment timings, hospitalization durations and toxicities. However, LEAM was associated with a lower post-ASCT disease progression rate than CCVP-16 in the whole cohort and in the Hodgkin lymphoma subgroup. Overall survival did not differ between the two regimens in the whole cohort and in Hodgkin lymphoma and diffuse large B cell lymphoma subgroups. In contrast, progression free survival was superior with LEAM in comparison to CCVP-16 in the whole cohort and in the Hodgkin lymphoma subgroup.
LEAM is more effective than CCVP-16 in ASCT for lymphoma, especially Hodgkin lymphoma, and has a comparable toxicity profile.
Vorheriger Artikel Patient-reported outcomes and psycho-oncological screening in hematology: a practical example of routine electronic monitoring
Nächster Artikel Adjuvant and neoadjuvant treatment of melanoma
Literatur
1.
Filmont JE, Gisselbrecht C, Cuenca X, et al. The impact of pre- and post-transplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation. Cancer. 2007;110:1361–9.CrossRef
2.
Armitage JO. Treatment of non-Hodgkin’s lymphoma. N Engl J Med. 1993;328:1023–30.CrossRef
3.
Colpo A, Hochberg E, Chen YB. Current status of autologous stem cell transplantation in relapsed and refractory Hodgkin’s lymphoma. Oncologist. 2012;17:80–90.CrossRef
4.
Nademanee A. Transplantation for non-Hodgkin lymphoma. Expert Rev Hematol. 2009;2:425–42.CrossRef
5.
Rezvani AR, Storb RF. Separation of graft-vs.-tumor effects from graft-vs.-host disease in allogeneic hematopoietic cell transplantation. J Autoimmun. 2008;30(3):172–9.CrossRef
6.
Mounier N, Gisselbrecht C. Conditioning regimens before transplantation in patients with aggressive non-Hodgkin’s lymphoma. Ann Oncol. 1998;9(Suppl. I):S15–S21.CrossRef
7.
Sharma A, Kayal S, Iqbal S, Malik PS, Raina V. Comparison of BEAM vs. LEAM regimen in autologous transplant for lymphoma at AIIMS. SpringerPlus. 2013;2:489.CrossRef
8.
Stuart MJ, Chao NS, Horning SJ, et al. Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin’s disease. Biol Blood Marrow Transplant. 2001;7:552–60.CrossRef
9.
Fernandez HF, Escalon MP, Pereira D, Lazarus HM. Autotransplant conditioning regimens for aggressive lymphoma: are we on the right road? Bone Marrow Transplant. 2007;40:505–13.CrossRef
10.
Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912–9.CrossRef
11.
Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–67.CrossRef
12.
Mabed M, Shamaa S. High-dose chemotherapy plus non-cryopreserved autologous peripheral blood stem cell transplantation rescue for patients with refractory or relapsed Hodgkin disease. Biol Blood Marrow Transplant. 2006;12:942–8.CrossRef
13.
Ramzi M, Mohamadian M, Vojdani R, et al. Autologous non-cryopreserved hematopoietic stem cell transplant with CEAM as a modified conditioning regimen in patients with Hodgkin lymphoma: a single-center experience with a new protocol. Exp Clin Transplant. 2012;2:163–7.CrossRef
14.
15.
Salar A, Sierra J, Gandarillas M, et al. Autologous stem cell transplantation for clinically aggressive non-Hodgkin’s lymphoma: the role of preparative regimens. Bone Marrow Transplant. 2001;27(4):405–12.CrossRef
16.
Majhail NS, Ness KK, Burns LJ, et al. Late effects in survivors of Hodgkin and non-Hodgkin lymphoma treated with autologous hematopoietic cell transplantation: a report from the bone marrow transplant survivor study. Biol Blood Marrow Transplant. 2007;13:1153–9.CrossRef
17.
Gutierrez-Delgado F, Maloney DG, Press OW, et al. Autologous stem cell transplantation for non-Hodgkin’s lymphoma: comparison of radiation-based and chemotherapy-only preparative regimens. Bone Marrow Transplant. 2001;28:455–61.CrossRef
18.
Caballero MD, Rubio V, Rifon J, et al. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant. 1997;20:451–8.CrossRef
19.
Alessandrino EP, Bernasconi P, Colombo A, et al. Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies. Bone Marrow Transplant. 2000;25:309–13.CrossRef
20.
Cordonnier C, Vernant JP, Mital P, Lange F, Bernaudin JF, Rochant H. Pulmonary fibrosis subsequent to high doses of CCNU for chronic myeloid leukemia. Cancer. 1983;51:1814–8.CrossRef
21.
Charley C, Babic A, Bargalló Arraut I, Ferrero I. JACIE and quality management in HSCT: implications for nursing. In: Kenyon M, Babic A, editors. The European blood and marrow transplantation textbook for nurses. Cham: Springer; 2018. pp. 1–22.
22.
Chen YB, Lane AA, Logan B, et al. Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2015;21(6):1046–53.CrossRef
23.
Gupta A, Gokarn A, Rajamanickam D, et al. Lomustine, cytarabine, cyclophosphamide, etoposide—an effective conditioning regimen in autologous hematopoietic stem cell transplant for primary refractory or relapsed lymphoma: Analysis of toxicity, long-term outcome, and prognostic factors. J Cancer Res Ther. 2018;14(5):926–33.CrossRef
24.
Zhang J, Grubor V, Love CL, et al. Genetic heterogeneity of diffuse large B‑cell lymphoma. Proc Natl Acad Sci U S A. 2013;110(4):1398–403.CrossRef
25.
Shu Z, Heimfeld S, Gao D. Hematopoietic stem cell transplantation with cryopreserved grafts: adverse reactions after transplantation and cryoprotectant removal prior to infusion. Bone Marrow Transplant. 2014;49:469–76.CrossRef
Metadaten
Titel
Comparison of outcomes of two non-BCNU-containing conditioning regimens used in autologous stem cell transplantation for relapsed/refractory lymphoma
verfasst von
Amro Mohamed Sedky El-Ghammaz
Maha El-Zimaity
Afaf Abdel-Aziz Abdel-Ghaffar
Publikationsdatum
25.05.2020
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2020
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-020-00621-0

Weitere Artikel der Ausgabe 3/2020

San Antonio Breast Cancer Symposium 2019: human epidermal growth factor receptor 2(HER2)-positive breast cancer and image-guided biopsy to detect pathologic complete response (pCR)

  • short review

Chemoradiotherapy alone or chemoradiotherapy followed by surgery in rectal cancer

  • short review

New systemic treatment options in mycosis fungoides and Sézary syndrome

  • Open Access
  • short review

Fine-tuning front-line therapy in chronic lymphocytic leukemia

  • Open Access
  • short review

Biologically effective dose and overall survival in stereotactic body radiotherapy for lung tumors

  • original report

Managing an oncology clinic during the COVID-19 pandemic—how we did it in Sarajevo?

  • editorial